Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 2/20 | 0.36 |
| ▸ | SKP1 | P63208 | 2/20 | 0.36 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.36 |
| ▸ | RET | P07949 | 9/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23208999 | 1.00 | CKS1B (0.36) | CKS1BSKP1SKP2RETJAK3 | |
| SCHEMBL23208716 | 1.00 | CKS1B (0.36) | CKS1BSKP1SKP2RETJAK3 | |
| SCHEMBL23209044 | 0.90 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL23209115 | 0.90 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL23209040 | 0.90 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL23208715 | 0.90 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL29970264 | 0.83 | RET (0.35) | CKS1BSKP1SKP2RETJAK3 | |
| SCHEMBL29970820 | 0.83 | PTPN11 (0.46) | RETJAK3BTKMAP4K4 | |
| SCHEMBL29970903 | 0.83 | PTPN11 (0.46) | RETJAK3BTKMAP4K4 | |
| SCHEMBL29970892 | 0.83 | PTPN11 (0.46) | RETJAK3BTKMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11466016-B2 | Pharmaceutical compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-10-11 | — | — | US | disclosed |
| US-20210107908-A1 | PHARMACEUTICAL COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107908-A1 | PHARMACEUTICAL COMPOUNDS | MAPT, CYP3A5, SLC5A1 | CKS1B 2030/4885SKP1 167/4885SKP2 1472/4885 |
| US-11466016-B2 | Pharmaceutical compounds | MAPT, CYP3A5, SLC5A1 | CKS1B 2030/4885SKP1 167/4885SKP2 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.